Research & Development, Quality and Human Resources departments under new leadership of seasoned professionals
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.
Dr. Eric Wittchow, Vice President and new Head of R&D, brings more than 20 years of international experience in the development of combination products at both mid- and large-size MedTech and pharmaceutical companies. His innovative ideas in the field of bio-degradable materials as well as local drug delivery have led to several approvals, patents, and publications. His strong scientific background combined with his experience in steering interdisciplinary teams of R&D experts ideally complements AMW’s leadership team. Dr. Wittchow studied Chemistry and a minor in polymer chemistry and pharmacology at Universities in Erlangen-Nuremberg, Heidelberg, Marburg and Bonn.
As Vice President Quality, Dr. Martina Wilhelm heads the overall management of quality control and quality assurance at AMW. She has been working within the GMP-regulated environment for more than 20 years, from setting-up to complete steering of quality teams and structures. Throughout her career, Dr. Wilhelm has also held the position of Qualified Person at various pharmaceutical companies. She studied Chemistry and holds a PhD from Technical University of Munich, Germany.
Carolin Unger heads the HR department as Vice President Human Resources. In her 15 years’ experience in leading positions, she was responsible for implementing HR strategies as well as establishing and managing all relevant HR services in an international environment. Her focus on participative leadership, innovative recruitment and modern human resources management will ideally support AMW in further recruiting top talents and thereby supporting AMW’s growth strategy. Ms. Unger holds a diploma from Munich University of Applied Sciences, Germany.
“We are delighted to welcome Eric, Martina and Carolin to our team, all three proven experts in their field,” said Dr. Konstantin Petropoulos, CEO of AMW. “A leadership team with a demonstrated track record in our industry and beyond, will be invaluable as we move into the next stage of AMW’s growth. Moreover, their enthusiastic mindset will further drive our corporate DNA to pursue our goal of improving the lives of patients worldwide by providing them access to value-added medicines or cost-effective alternative therapies.”
AMW GmbH is a specialty pharmaceutical company focused on innovative bio-degradable sustained-release drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four marketed products (goserelin & leuprorelin implants, rivastigmine & buprenorphine patches).
AMW is based in Warngau, south of Munich, Germany.
For further information, please contact:
Dr. Konstantin Petropoulos
Phone: +49 8024 470999-0